Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals, John Strickler, M.D.

Conditions

Colon CancerEndometrial CancerFallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer

Phase 1

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

RecruitingNCT04590326

Regeneron PharmaceuticalsEndometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer +1

Start: 2020-12-08End: 2027-11-30Target: 612Updated: 2025-11-21

Phase 2

Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer

Not yet recruitingNCT07224022

John Strickler, M.D.Colon Cancer

Start: 2026-02-01End: 2029-07-01Target: 24Updated: 2026-02-04

Related Papers

A phase I/II, multicenter, open-label study of REGN5668 (mucin [MUC]16 x CD28 bispecific antibody [bsAb]) with cemiplimab (programmed death [PD]-1 Ab) or REGN4018 (MUC16 x CD3 bsAb) in recurrent ovarian cancer (rOVCA).

Journal of Clinical Oncology2021-05-205 citations